Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab versus placebo for airway inflammation in chronic obstructive pulmonary disease
ISRCTN14181775Phase 2Recruiting
- Sponsor
- University of Leicester
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezepelumab with Placebo (2 arms). Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN14181775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14181775.